CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Phone315-797-8375
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$859.63 million
Profitability
Miscellaneous
Employees3,100
Next Earnings Date1/29/2020 (Confirmed)
OptionableOptionable
CONMED (NASDAQ:CNMD) Frequently Asked Questions
What is CONMED's stock symbol?
CONMED trades on the NASDAQ under the ticker symbol "CNMD."
How often does CONMED pay dividends? What is the dividend yield for CONMED?
CONMED announced a quarterly dividend on Thursday, November 21st. Investors of record on Friday, December 13th will be given a dividend of $0.20 per share on Tuesday, January 7th. This represents a $0.80 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend is Thursday, December 12th. View CONMED's Dividend History.
How were CONMED's earnings last quarter?
CONMED Co. (NASDAQ:CNMD) posted its quarterly earnings data on Wednesday, October, 30th. The medical technology company reported $0.62 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.56 by $0.06. The medical technology company had revenue of $233.60 million for the quarter, compared to analyst estimates of $228.12 million. CONMED had a return on equity of 10.50% and a net margin of 3.15%. The business's revenue for the quarter was up 15.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.46 EPS. View CONMED's Earnings History.
When is CONMED's next earnings date?
How can I listen to CONMED's earnings call?
CONMED will be holding an earnings conference call on Wednesday, January 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has CONMED issued on next quarter's earnings?
CONMED issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided EPS guidance of $2.62-2.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.28. The company issued revenue guidance of $954.96 million, compared to the consensus revenue estimate of prior $2.52-2.57.
What price target have analysts set for CNMD?
5 equities research analysts have issued 1 year target prices for CONMED's stock. Their forecasts range from $99.00 to $136.00. On average, they anticipate CONMED's stock price to reach $113.00 in the next twelve months. This suggests a possible upside of 4.6% from the stock's current price. View Analyst Price Targets for CONMED.
What is the consensus analysts' recommendation for CONMED?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CONMED.
Has CONMED been receiving favorable news coverage?
Headlines about CNMD stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. CONMED earned a daily sentiment score of -4.5 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for CONMED.
Are investors shorting CONMED?
CONMED saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 1,050,000 shares, an increase of 8.1% from the November 28th total of 971,700 shares. Based on an average daily trading volume, of 230,200 shares, the days-to-cover ratio is currently 4.6 days. Approximately 3.7% of the shares of the stock are short sold. View CONMED's Current Options Chain.
Who are some of CONMED's key competitors?
Some companies that are related to CONMED include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).
What other stocks do shareholders of CONMED own?
Who are CONMED's key executives?
CONMED's management team includes the folowing people:
- Mr. Curt R. Hartman, CEO, Pres & Director (Age 55)
- Mr. Todd W. Garner, Exec. VP & CFO (Age 50)
- Mr. Patrick J. Beyer, Pres of CONMED International (Age 53)
- Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 44)
- Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 44)
Who are CONMED's major shareholders?
CONMED's stock is owned by a number of of retail and institutional investors. Top institutional investors include Columbus Circle Investors (0.90%), Strs Ohio (0.20%), Mckinley Capital Management LLC Delaware (0.09%), State of Alaska Department of Revenue (0.08%), Campbell & CO Investment Adviser LLC (0.06%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own CONMED stock include Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, John Jed Kennedy, Johonna Marie Pelletier, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED.
Which major investors are selling CONMED stock?
CNMD stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Columbus Circle Investors, Louisiana State Employees Retirement System, Diversified Trust Co and State of Alaska Department of Revenue. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Dirk Kuyper, John Jed Kennedy, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED.
Which major investors are buying CONMED stock?
CNMD stock was bought by a variety of institutional investors in the last quarter, including Mckinley Capital Management LLC Delaware, Campbell & CO Investment Adviser LLC, Strs Ohio, Eqis Capital Management Inc. and Exchange Traded Concepts LLC. View Insider Buying and Selling for CONMED.
How do I buy shares of CONMED?
Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CONMED's stock price today?
One share of CNMD stock can currently be purchased for approximately $108.00.
How big of a company is CONMED?
CONMED has a market capitalization of $3.07 billion and generates $859.63 million in revenue each year. The medical technology company earns $40.85 million in net income (profit) each year or $2.18 on an earnings per share basis. CONMED employs 3,100 workers across the globe.View Additional Information About CONMED.
What is CONMED's official website?
How can I contact CONMED?
CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.
MarketBeat Community Rating for CONMED (NASDAQ CNMD)
MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
